Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Jim Cramer, the host of Mad Money, cautioned viewers on Wednesday about the risks of blindly following the crowd in the stock ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Johnson & Johnson (NYSE:JNJ) is a healthcare company engaged in the research, development, manufacturing, and marketing of a ...

Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson & Johnson Inc. has a lower P/E ratio ...

From what we can see, insiders were net sellers in Johnson & Johnson's ( NYSE:JNJ ) during the past 12 months. That ...

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...